Ceribell, Inc.: Strong Q1 Performance and Promising Growth Justify Buy Rating

TD Cowen analyst Josh Jennings has maintained their bullish stance on CBLL stock, giving a Buy rating on May 9.

Josh Jennings has given his Buy rating due to a combination of factors that highlight Ceribell, Inc.’s promising growth trajectory and robust market position. The company recently reported a strong first-quarter performance, with a notable increase in revenue by 42%, reaching $20.5 million. This growth is supported by a steady expansion in active accounts, which rose to 558 by the end of the first quarter, and an increase in utilization rates of their Ceribell System, indicating a significant market opportunity in the acute care setting.
Moreover, Ceribell’s management has expressed confidence in their ability to meet the 2025 guidance, despite potential tariff challenges. They have revised their total revenue expectations upwards to a range of $83 million to $87 million, supported by a robust pipeline of new deals and anticipated purchase orders. These factors, combined with the company’s underpenetrated market segments, suggest a strong potential for future growth, justifying the Buy rating.

According to TipRanks, Jennings is a 4-star analyst with an average return of 3.6% and a 50.70% success rate. Jennings covers the Healthcare sector, focusing on stocks such as Abbott Laboratories, Establishment Labs Holdings, and Medtronic.